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Abstract
When making clinical decisions concerning additional treatment for patients who have undergone radical prostatectomy (RP),
adverse laboratory/pathological features are considered major factors. We investigated and compared the prognostic efficacy of
adverse laboratory/pathological features in predicting overall survival (OS) and biochemical failure (BCF) in these patients.
The Korean Prostate Cancer Database was used to identify patients undergoing RP between May 2001 and April 2013. Patients
with incomplete clinicopathological data or positive lymphadenectomy results were excluded. Finally, 4486 patients included in the
final analysis were categorized based on their adverse laboratory/pathological features.
Adverse pathological features and detectable prostate-specific antigen (PSA) levels 6 weeks after surgery were observed in 1977
(44.1%) and 634 (14.1%) patients, respectively. PSA levels, pathological Gleason score ≥8, adverse pathological features [positive
surgical margin (PSM), seminal vesicle invasion (SVI), and extracapsular extension (ECE)], and adverse laboratory features (detectable
PSA levels after 6 weeks) together were significant predictors of BCF-free survival (BCFFS). SVI was identified as a predictor of OS.
Additionally, patients with ECE, PSM, and detectable PSA levels after 6 weeks, but without SVI, showed similar OS to those without
ECE, PSM, and detectable PSA levels after 6 weeks and with SVI (log-rank test, P= .976).
We successfully stratified patients based on adverse laboratory/pathological features after RP and demonstrated that these are
important prognostic factors for OS and BCFFS. Additionally, we identified the criteria for selecting appropriate patients for
undergoing additional treatment based on OS and BCFFS.
Abbreviations: ADT = androgen deprivation therapy, ART = adjuvant radiotherapy, BCF = biochemical failure, BCFFS = BCF-
free survival, BMI = body mass index, CCI = Charlson comorbidity index, CI = confidence interval, ECE = extracapsular extension,
HR = hazard ratio, MRI = magnetic resonance imaging, NCCN = National Comprehensive Cancer Network, OS = overall survival,
PCa = prostate cancer, PSA = prostate-specific antigen, PSM = positive surgical margin, PV = prostate volume, RP = radical
prostatectomy, RT = radiotherapy, SRT = salvage radiotherapy, SVI = seminal vesicle invasion, TV = tumor volume.
Keywords: prostatectomy, prostatic neoplasm, risk assessment, survival
1. Introduction
Radical prostatectomy (RP) is a widely chosen treatment option
for patients with localized prostate cancer (PCa) worldwide.[1,2]
However, some patients undergoing RP experience biochemical
failure (BCF) or show adverse pathological features such
as positive surgical margin (PSM), seminal vesicle invasion
(SVI), and extracapsular extension (ECE). For these patients,
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postoperative radiotherapy (RT) including adjuvant radiothera-
py (ART) and salvage radiotherapy (SRT) is recommended as an
additional treatment.[3–6] Based on high-level evidence from large
randomized clinical trials, the National Comprehensive Cancer
Network (NCCN), American, and European guidelines have
recommended ART for patients with adverse laboratory/
pathological features after RP.[6–8]
According to recent studies, clinical practices demonstrated
that frequency of radiotherapy use has not increased or declined,
although ART can improve oncological outcomes.[9–11] More-
over, ART was not considered to be a significant prognostic
factor for overall survival (OS).[12] These findings suggest that
more precise criteria, based on the survival of PCa patients, are
required to select patients for postoperative radiotherapy.
Although PSM, SVI, ECE, and BCF are known to be predictors
for poor oncological outcomes, we do not know which factors
might be more significantly involved with the oncological
outcomes. By investigating the most significant predictors for
oncological outcomes, we could develop nomograms to predict
poor oncological outcomes thereby help clinicians decide on
postoperative RT. Therefore, we classified a large cohort of
patients who had undergone RP depending on their adverse
laboratory/pathological features. Moreover, we investigated and
compared the prognostic efficacy of adverse laboratory and
pathological features in predicting OS and BCF.
2. Materials and methods
2.1. Study population and data collection
This study was approved by our institutional review board
(2016-0493-001). The Korean Prostate Cancer Database
(K-CaP), which was the first registry to comprehensively collect
data regarding Korean patients with PCa undergoing RP, was
used to identify patients.[13] A total of 6735 consecutive patients
with PCa who underwent RP between 2001 and 2012 were
selected from 5 Korean tertiary referral hospitals (Asan Medical
Center, Samsung Medical Center, Seoul National University
Bundang Hospital, Seoul St. Mary’s Hospital, and Yonsei
University Severance Hospital). Patient records were anonymized
and de-identified before analysis.
2.2. Assessments of clinicopathological variables
Clinicopathological data, including age at diagnosis, body mass
index (BMI), Charlson comorbidity index (CCI), PSA level at
diagnosis, prostate volume (PV) in preoperative imaging studies,
pathological outcomes [pathological stage, Gleason score, tumor
volume (TV), and adverse pathological features (ECE, SVI, and
PSM)], and follow-up PSA levels, were extracted from the K-CaP
registry. Patients with incomplete clinicopathological data, those
undergoing neoadjuvant androgen deprivation therapy (ADT),
or those with positive lymphadenectomy results were excluded.
Finally, 4486 patients were included in the final analysis.
Themagnetic resonance imaging (MRI) data of all patientswere
interpreted by radiologists from the urology department at each
participating hospital. The final pathology was determined using
RP specimens and reported by the pathologists from the urology
department of each institution. The clinicopathological stage was
assigned according to the tumor/node/metastasis staging system.
To analyze the preoperative risk, we categorized patients into 3
risk categories, including low (PSA<10ng/ml, biopsy Gleason
score 6, clinical stage <T2a), high (PSA>20ng/ml, biopsy
Gleason score ≥8, clinical stage ≥T3a), and intermediate
(patients who did not meet the criteria for the high- or low-
risk groups).
2.3. Pathological finding assessments
We analyzed pathological factors including the final pathological
stage, Gleason score, TV, ECE, SVI, and PSM. Adverse
pathological features were defined as ECE, SVI and PSM.
2.4. Follow-up PSA assessments
PSA was considered undetectable at a level of <0.01ng/ml, as
seen on an ultrasensitive assay. The time to PSA nadir was defined
as the duration from the day of surgery to the time when the PSA
level reached its nadir. For patients who showed detectable PSA
levels at the PSA nadir, the time to PSA nadir was considered to be
that at 6 weeks after RP. All patients were classified depending on
the presence of detectable PSA levels after 6 weeks.
BCF was characterized by a confirmed increase of more
than 0.2ng/ml (threshold) in the PSA level; failure of the PSA
level to decrease to undetectable levels; or the existence of
additional therapy, including radiotherapy, ADT, or both for
consecutive PSA increases, even if they did not reach the
threshold of 0.2ng/ml.
2.5. Statistical analyses
Continuous variables are expressed as medians (interquartile
ranges). Categorical variables are reported as numbers and
frequencies. Student t test was used to compare continuous
variables, and Chi-Squared test was used to compare categorical
variables. Simple and multiple logistic regressions with forward
selection were used. Survival curves were established using the
Kaplan–Meier method and compared using the log-rank test.
Prognostic factors were established using univariate analysis, and
the factors significant in univariate analysis were entered into
multivariate analysis using the Cox stepwise regression method.
No harmful collinearity among prognostic factors identified in
multivariate analysis was confirmed using coefficients of variance
inflation below 10. All statistical comparisons were conducted
using IBM SPSS Statistics, version 23 (IBM Corporation,




Table 1 summarizes the clinicopathological characteristics of the
study patients. Among 4486 patients, the mean age and PSA
levels were 72.0 years and 6.70ng/ml, respectively. These
parameters were significantly higher in the high-risk PCa group
than in the low- and intermediate-risk PCa groups. The mean PV
and TV were 32.2 cc and 2.6 cc, respectively, and both volumes
significantly increased as the risk of PCa increased.
With regard to adverse pathological features, PSM was the
most feature reported in 1379 patients (30.7%), followed by
ECE, which was reported in 1207 patients (26.9%). SVI was
observed in 334 patients (7.4%). Each adverse pathological
feature increased as the risk of PCa increased. All 3 adverse
pathological features were found in 176 patients (3.9%).
Park et al. Medicine (2019) 98:45 Medicine
2
With regard to adverse laboratory features, 634 patients
(14.1%) showed detectable PSA levels after 6 weeks. BCF was
noted in 915 patients and the mean time to BCF and 5-year BCF-
free survival (BCFFS) rate were 23.0 months and 63.3%,
respectively. Detectable PSA levels after 6 weeks and the
proportion of patients with BCF significantly increased with
the risk of PCa.
3.2. Prognostic significance of adverse laboratory/
pathological features in BCF
The Cox proportional hazards regression analyses of BCF are
presented in Table 2. In univariate analysis, preoperative PSA
levels, pathological Gleason score ≥8, ECE, SVI, PSM, and
detectable PSA levels after 6 weeks were associated with BCF. In
multivariate analysis, preoperative PSA levels [hazard ratio (HR):
1.01; 95% confidence interval (CI) 1.001–1.011, P< .001],
pathological Gleason score ≥8 (HR: 1.99; 95% CI 1.569–2.502,
P< .001), ECE (HR: 1.44; 95% CI 1.152–1.802, P= .001), SVI
(HR: 2.24; 95% CI 1.696–2.944, P< .001), PSM (HR: 2.07;
95%CI 1.694–2.531, P< .001), and detectable PSA levels after 6
weeks (HR: 2.06; 95% CI 1.703–2.488, P< .001) remained
independent predictors of BCF.
3.3. Determination of BCFFS by stratifying the
combination of adverse pathological features
We compared the BCFFS based on the combination of adverse
pathological features (Table 3). Incidence of BCF was highest in
the group with SVI and PSM, but without ECE (60.7%). Patients
Table 1
Characteristics of patients in the low-, intermediate-, and high-risk prostate cancer groups.
Total Low risk Intermediate risk High risk P value
Number of patients (n, (%)) 4486 1483 (33.1) 2,014 (44.9) 989 (22.0)
Age (years) 72.0 (67.0–76.0) 71.0 (66.0–75.0) 72.0 (67.0–77.0) 73.0 (67.0–77.0) <.001
CCI (≥3) 26 (0.6) 3 (0.2) 14 (0.7) 9 (0.9) .050
BMI (kg/cm2) 24.3 (22.6–26.1) 24.3 (22.6–26.0) 24.4 (22.6–26.1) 24.3 (22.5–26.1) .708
PSA (ng/mL) 6.70 (4.72–10.78) 5.17 (4.01–6.78) 7.32 (5.05–11.27) 13.0 (6.76–25.32) <.001
Prostate volume (cc) 32.2 (25.2–42.0) 34.4 (27.0–45.0) 31.0 (24.7–40.0) 32.0 (26.0–41.0) <.001
Tumor volume (cc) 2.6 (1.1–5.6) 1.5 (0.6–3.0) 2.8 (1.4–5.4) 5.4 (2.4–10.8) <.001
Pathological Gleason score (n, (%)) <.001
7 3954 (88.1) 1459 (98.4) 1899 (94.3) 596 (60.3)
≥8 532 (11.9) 24 (1.6) 115 (5.7) 393 (39.7)
Pathological stage (n, (%)) <.001
T2 3180 (70.9) 1482 (99.9) 1237 (61.4) 461 (46.6)
T3 1306 (29.1) 1 (0.1) 777 (38.6) 528 (53.4)
Adverse pathological features (n, (%))
Extracapsular extension 1207 (26.9) 1 (0.1) 724 (35.9) 482 (48.7) <.001
Seminal vesicle invasion 334 (7.4) 0 (0.0) 137 (6.8) 197 (19.9) <.001
Positive surgical margins 1379 (30.7) 264 (17.8) 676 (33.6) 439 (44.4) <.001
Number of adverse pathological features (n, (%)) <0001
0 2509 (55.9) 1218 (82.1) 952 (47.3) 339 (34.3)
1 1210 (27.0) 265 (17.9) 647 (32.1) 298 (30.1)
2 591 (13.2) 0 (0.0) 355 (17.6) 236 (23.9)
3 176 (3.9) 0 (0.0) 60 (3.0) 116 (11.7)
Detectable PSA levels after 6 weeks (n, (%)) 634 (14.1) 177 (11.9) 272 (13.5) 185 (18.7) <0001
BCF [n, (%)] 915 (20.4) 142 (15.5) 397 (19.7) 376 (38.0)
Time to BCF (months) 23.0 (10.1–40.6) 27.7 (16.0–50.5) 24.1 (10.5–41.0) 20.2 (8.1–36.8) <.001
5-year BCFFS (%) 63.3 80.7 63.8 37.7 <0001
BCF within 1 year (n, (%)) 266 (5.9) 23 (1.6) 108 (5.4) 135 (13.7) <.001
Follow-up (years) 43.1 (21.6–67.2) 42.9 (23.3–67.7) 44.1 (21.2–67.5) 41.0 (19.8–65.8) .417
Values are presented as the number (%) or median (interquartile range).
BCF=biochemical failure, BCFFS=BCF-free survival, BMI=body mass index, CCI=Charlson comorbidity index, PSA=prostate-specific antigen.
Table 2
Univariate and multivariate analyses to identify the significant predictors of postoperative biochemical failure.
Univariate analysis Multivariate analysis
Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
Age 1.00 (0.989–1.008) .818
PSA levels 1.01 (1.010–1.013) <.001 1.01 (1.001–1.011) <.001
Pathological Gleason score (≥8) 3.23 (2.778–3.759) <.001 1.99 (1.569–2.502) <.001
Extracapsular extension 2.71 (2.377–3.088) <.001 1.44 (1.152–1.802) .001
Seminal vesicle invasion 4.34 (3.75–5.130) <.001 2.24 (1.696–2.944) <.001
Positive surgical margins 2.73 (2.397–3.108) <.001 2.07 (1.694–2.531) <.001
Detectable PSA levels after 6 weeks 2.42 (2.005–2.913) <.001 2.06 (1.703–2.488) <.001
CI= confidence interval, LVI= lymphovascular invasion, PNI=perineural invasion, PSA=prostate-specific antigen.
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with all pathological features showed slightly lower rates of BCF
(52.8%). On comparing each adverse pathological feature, SVI
was the most significant factor for the prediction of BCF. Time to
BCF significantly decreased with every pathological feature.
3.4. Prognostic significance of adverse laboratory/
pathological features in overall survival
Cox proportional hazards regression analyses were performed
for the determining the prognostic factors for OS (Table 4). The
5-year OS rate was 97.8%. In univariate analysis, age, CCI (≥3),
pathological Gleason score ≥8, ECE, SVI, PSM, and detectable
PSA levels after 6 weeks were associated with OS. In multivariate
analysis, age (HR: 1.01; 95%CI: 1.049–1.122, P< .001) and SVI
(HR: 1.99; 95% CI 1.078–3.686, P= .028) were the only
significant predictors of OS. Detectable PSA levels after 6 weeks
was not identified as a predictor of OS in multivariate analysis.
3.5. Determination of OS by stratifying adverse laboratory/
pathological features
We tried to identify patients without SVI having similar OS rates
to patients with only SVI as an adverse laboratory/pathological
feature. For this subgroup analysis, patients were classified
according to the presence of ECE, PSM, or detectable PSA after 6
weeks: [Group 1: SVI (+); Group 2: SVI/ECE/PSM/PSA (-/+/+/+);
Group 3: SVI/ECE/PSM/PSA (-/+/+/-), or SVI/ECE/PSM/PSA
(-/-/+/+), or SVI/ECE/PSM/PSA (-/+/-/+); Group 4: SVI/ECE/PSM/
PSA (-/-/-/+), or SVI/ECE/PSM/PSA (-/-/+/-), or SVI/ECE/PSM/
PSA (-/+/-/-); and Group 5: SVI/ECE/PSM/PSA (-/-/-/-)]. After
adjustment for covariates, we found that the groups with a higher
number of adverse laboratory/pathological features were associ-
ated with poor OS (log-rank test, P< .001). Notably, patients in
Group 2 (with ECE, PSM, and detectable PSA levels after 6 weeks
as risk factors) and Group 1 (with SVI) have poor OS compared
with those in Groups 3 to 5; further, there were no differences in
OS between Groups 1 and 2 (log-rank test, P= .976) (Fig. 1).
4. Discussion
We investigated BCFFS and OS based on adverse laboratory/
pathological features. As expected, adverse laboratory/patholog-
ical features were significant prognostic factors for BCFFS.
Additionally, SVI presented with the highest HR of predicting
BCFFS, followed by PSM, detectable PSA levels after 6 weeks,
pathological Gleason score, ECE, and PSA, in that order.
Notably, of the adverse laboratory and pathological features, SVI
was identified as the significant predictor for OS. Moreover, we
found that patients without SVI and with ECE, PSM, and
detectable PSA levels showed a similar OS to those with SVI and
without ECE, PSM, and detectable PSA levels. Therefore, this
study suggested that patients with SVI or those without SVI but
with all ECE, PSM, and detectable PSA after 6 weeks should
immediately be considered for multidisciplinary management
(RT, RT +ADT, or ADT) postoperatively, and those not showing
these features may undergo treatment based on the patient’s and
physician’s preferences.
NCCN guidelines suggest that ART after recuperation from
RP is likely beneficial in patients with 1 or more adverse
laboratory or pathological features.[6] However, for adverse
laboratory features, there was no definite time point for the
measurement of postoperative PSA. In patients with a detectable
PSA level, clinicians doubt the likelihood of cancer recurrence or
residual cancer. Theoretically, PSA nadir, which decreases along
with PSA’s half-life, should be undetectable post-RP.[14] To
determine the PSA nadir for prognosis, the exact follow-up time
Table 3
Biochemical failure outcomes of prostate cancer patients who were treated with radical prostatectomy, stratified by the number of
adverse pathological features.
ECE SVI PSM ECE+SVI ECE+PSM SVI+PSM ECE+PSM+SVI P value
BCF (n, (%)) 98 (20.9) 20 (43.5) 192 (27.6) 42 (50.0) 173 (36.1) 17 (60.7) 93 (52.8) <.001
Time to BCF (months) 20.7 18.0 24.6 18.2 20.6 21.4 9.3 <.001
5-year BCFFS (%) 62.0 22.8 52.4 24.0 47.2 7.9 25.4 <.001
OS (n, (%)) 42 (1.7) 14 (3.0) 19 (2.7) 1 (1.2) 16 (3.3) 0 (0.0) 13 (7.4) .028
Time to OS (months) 53.0 N/A 45.0 61.2 47.8 N/A 29.9 .809
5-year OS (%) 88.6 100.0 93.3 91.0 91.2 100.0 85.5 <.001
The values are presented as a number (%) or median (interquartile range).
BCF=biochemical failure, BCFFS=BCF-free survival, PSA=prostate-specific antigen.
Table 4
Univariate and multivariate analyses to identify the significant predictors of overall survival.
Univariate analysis Multivariate analysis
Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
Age 1.10 (1.059–1.131) <.001 1.09 (1.051–1.125) <.001
PSA 1.01 (0.999–1.016) .094
CCI (≥3) 4.17 (1.026–16.914) .046 3.33 (0.807–13.763) .096
Pathological Gleason score (≥8) 1.99 (1.234–3.212) .005 1.66 (0.965–2.845) .067
Extracapsular extension 2.01 (1.365–2.966) <.001 1.27 (0.771–2.075) .352
Seminal vesicle invasion 2.12 (1.210–3.729) .009 1.99 (1.078–3.686) .028
Positive surgical margins 1.72 (1.168–2.520) .006 1.31 (0.832–2.061) .244
Detectable PSA after 6 weeks 1.27 (0.816–1.969) .290
CCI=Charlson comorbidity index, CI= confidence interval, PSA=prostate-specific antigen.
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should be evaluated. Several studies have suggested that the 6-
week period is the most useful for detecting PSA at its nadir.[15,16]
Our results presenting the efficacy of detectable PSA after 6 weeks
for predicting BCFFS supported the results of previous studies.
No study has compared the prognostic significance of adverse
laboratory feature vs adverse pathological features stated in
NCCN guidelines.[6] Notably, to the best of our knowledge, this
is the first study to demonstrate that an adverse laboratory
feature, i.e., detectable PSA, has similar prognostic effects on
disease progression as adverse pathological features. According
to this study and previous studies that have emphasized on the
importance of histopathological findings,[17] clinicians should
not overlook patients who show undetectable PSA levels but have
adverse pathological features.
Amongadverse laboratory/pathological features, SVIwas found
to be the most significant factor for predicting BCFFS and OS.
Previous studies have also demonstrated the importance of SVI; it
was considered as negative prognostic factor of PCa and had a
significantly worse prognosis than that with only ECE.[18,19]
However, several studies reported that SVI is not associatedwith a
uniformlypoorprognosis and theprognosis couldbedependent on
the site of invasion.[20,21] We believe that the percentage of BCFFS
and OS would increase if the exact location of SVI was evaluated.
Because the 5-year progression-free survival rates approach
100% in patients with localized PCa, survivors should be
assessed for physical (urinary, sexual, and bowel) and psychoso-
cial effects of PCa and should be treated for those.[22,23]
Additional treatment after RP should be considered carefully
and precisely. Although ART could reduce the risk of PSA relapse
and disease recurrence, the period within 1 year after RP is crucial
for the recovery of continence and sexual function. Without the
precise indication for ART, some patients might not receive
timely ART and some may undergo overtreatment.
High-level evidence concerning the efficacy of ART from
several trials and the prognosis according to the patient’s
pathological features have been used to counsel patients
who require additional treatment.[3–5] However, the use of
postoperative radiotherapy for patients with PCa and adverse
pathological features has not been commonly reported.[10,11]
Moreover, the use of ART within 6 months after RP in patients
with PCa and adverse pathological features is paradoxically
declining.[9] This trend may be the result of multiple factors,
including the patient’s and physician’s preferences, toxicity
concerns, no consistent survival benefit in the updated random-
ized trials, or a growing preference for SRT at the time of PSA
recurrence, rather than ART.[12,24,25] We believed that there was
the need for a more precise criteria for selecting patients for
postoperative radiotherapy in clinical practice. We identified
the criteria for selecting patients who should receive ART on the
basis of OS and BCFFS. Finally, we recommend that patients with
SVI or without SVI but with ECE, PSM, detectable PSA levels
after 6 weeks should immediately be considered for multidisci-
plinary management postoperatively.
There are several limitations of this study. First, this is the
multi-center study that includes involvement of multiple
physicians and a variety of postoperative management measures.
Nevertheless, we believe that this effect is inherent in any
retrospective study and may reflect real-world clinical practice.
Second, although our study demonstrated the potential risk
factors to stratify patients who were eligible for ART, we did not
evaluate the efficacy of ART in patients with the identified risk
factors. We are planning to perform randomized clinical trials to
evaluate the impact of ART. Third, since we analyzed the
database which started from 15 years ago, there could be some
discrepancy in the pathological diagnosis criteria.
5. Conclusion
We successfully stratified patients according to the number of
adverse laboratory/pathological features after RP, and demon-
strated that these are important prognostic factors for OS and
BCFFS. Additionally, we identified the criteria for selecting
appropriate patients for undergoing additional treatment after
RP based on OS and BCFFS.
Figure 1. Overall survival in patients with seminal vesical invasion and the number of adverse laboratory/pathological features in patients without seminal vesical
invasion after adjusting for covariates.
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